Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) CEO Michael J. Rossi sold 3,917 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.20, for a total value of $20,368.40. Following the completion of the transaction, the chief executive officer now owns 137,083 shares of the company's stock, valued at $712,831.60. The trade was a 2.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Y-mAbs Therapeutics Stock Up 3.8 %
Shares of NASDAQ:YMAB traded up $0.18 during midday trading on Tuesday, hitting $4.94. 338,078 shares of the stock traded hands, compared to its average volume of 467,358. The stock has a market capitalization of $223.38 million, a PE ratio of -9.15 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a one year low of $4.25 and a one year high of $17.78. The business's 50 day moving average is $6.22 and its two-hundred day moving average is $10.38.
Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.50 million during the quarter, compared to analysts' expectations of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the business posted ($0.02) EPS. As a group, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.
Institutional Trading of Y-mAbs Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its position in Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company's stock valued at $15,909,000 after purchasing an additional 405,169 shares during the period. Barclays PLC boosted its stake in shares of Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company's stock valued at $910,000 after purchasing an additional 56,244 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock valued at $10,699,000 after buying an additional 47,846 shares during the period. Intech Investment Management LLC purchased a new position in shares of Y-mAbs Therapeutics during the third quarter valued at about $133,000. Finally, Caligan Partners LP raised its stake in Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock worth $15,718,000 after buying an additional 613,175 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company's stock.
Wall Street Analyst Weigh In
YMAB has been the subject of several research reports. Wedbush reaffirmed an "outperform" rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a "buy" rating and a $17.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Bank of America cut their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Finally, Oppenheimer initiated coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an "outperform" rating and a $23.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $19.30.
Check Out Our Latest Research Report on YMAB
Y-mAbs Therapeutics Company Profile
(
Get Free Report)
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Y-mAbs Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Y-mAbs Therapeutics wasn't on the list.
While Y-mAbs Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
